Avtor/Urednik		Antolič, Bor
Naslov		Testi strjevanja krvi med nosečnostjo pri zdravih in pri bolnicah z vensko trombozo
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Univerza v Ljubljani, Medicinska fakulteta
Leto izdaje		2003
Obseg		str. 49
Jezik		slo
Abstrakt		Background: Venous thromboembolism (VT) is a rare but serious complication of pregnancy and puerperium and with its acute phase complication - pulmonary embolism (PE) - constitutes the major cause of maternal morbidity and mortality. Low-molecular-weight heparin (LMWH), administered in weight-adjusted doses, is the treatment of choice for VT. Dosing of LMWH for treatment of VT and the need for thromboprophylaxis during pregnancy is contentious. Aim: To monitor the anticoagulant effect of LMWH in patients with an episode of VT in past or current pregnancy and to assess hemostatic system activation. Hypothesis: Dosing of LMWH during pregnancy needs not to be altered in proportion to the change in weight during pregnancy. The markers of hemostatic system activation increase during pregnancy. The increase of markers of hemostatic system activation is higher in pregnant women with VT than in healthy pregnant women. Methods: A prospective study was set in Ljubljana University Medical Centre. Twenty-two consecutive pregnant women, aged 20 to 42 (-x=32,0) yrs, with a past or present episode of VT, were included in the study between April 2001 and May 2003. The control group consisted of 9 healthy pregnant women, aged 24 to 38 (-x=31,2) yrs. We assigned our patients into three groups. Group A consisted of 11 pregnant women with VT in current pregnancy. They received LMWH dalteparin in initially weight-adjusted doses (100 IU/kg/bd or 200 IU/kg daily) during entire pregnancy. Group B consisted of 4 pregnant women with VT in their previous pregnancy. They received 2500 or 5000 IU of dalteparin daily. The dosing of dalteparin has not been altered during pregnancy. group C consisted of 7 pregnant women with VT in their previous pregnancy, with no pharmacological prophylaxis during current pregnancy. We performed serial monthly anti-Xa assays in all patients on dalteparin using chromogenic method. (Abstract truncated at 2000 characters)
Deskriptorji		THROMBOPHLEBITIS PREGNANCY COMPLICATIONS, HEMATOLOGIC PULMONARY EMBOLISM HEPARIN, LOW-MOLECULAR-WEIGHT FACTOR XA ADULT PROTHROMBIN THROMBIN FIBRIN ANTITHROMBINS PROSPECTIVE STUDIES PREGNANCY